Document is current
Any future updates will be listed below
-
Authors
Wright, Caroline F. https://orcid.org/0000-0003-2958-5076
Sharp, Luke N. https://orcid.org/0009-0001-3657-5493
Jackson, Leigh https://orcid.org/0000-0002-0260-5295
Murray, Anna https://orcid.org/0000-0002-2351-2522
Ware, James S. https://orcid.org/0000-0002-6110-5880
MacArthur, Daniel G.
Rehm, Heidi L. https://orcid.org/0000-0002-6025-0015
Patel, Kashyap A. https://orcid.org/0000-0002-9240-8104
Weedon, Michael N. https://orcid.org/0000-0002-6174-6135
-
Funding
Funding for this research was provided by:
Wellcome Trust (226083/Z/22/Z)
Wellcome Trust (226083/Z/22/Z)
RCUK | Medical Research Council (MR/T00200X/1)
Diabetes UK (19/0005994)
Diabetes UK (19/0005994)
RCUK | MRC | Medical Research Foundation (MR/T00200X/1)
- License Information
-
More Information
Article History
Received: 15 December 2023
Accepted: 24 June 2024
First Online: 29 July 2024
Competing interests
: M.N.W. is a co-investigator on a Randox Laboratories R&D research grant and received translational industry academic funding from Randox Laboratories R&D relating to autoimmune GRS for prediction and classification of disease. M.N.W. and K.A.P. have received royalties from Randox as co-inventors of a type 1 diabetes genetic risk score product. D.G.M. is a paid advisor to GlaxoSmithKline, Insitro, Variant Bio and Overtone Therapeutics and has received research support from AbbVie, Astellas, Biogen, BioMarin, Eisai, Google, Merck, Microsoft, Pfizer and Sanofi–Genzyme. J.S.W. has received research support from Bristol Myers Squibb and has acted as a consultant for MyoKardia, Pfizer, Foresite Labs, HealthLumen and Tenaya Therapeutics. The other authors have no conflict of interest to declare.
